Patient guide
Tablet, lozenge, or injection: the route is part of the product
Avoid treating every medicine with semaglutide in its name as the same formulation or evidence base.
Document research · No independent medical review claimedOn this page
An online menu may place tablets, lozenges, sublingual preparations, and injections near one another. It can be tempting to choose by price or convenience alone. The route and finished formulation also change the clinical questions that need answering.
Approval belongs to a specific product, not to every preparation with a familiar ingredient. A compounded oral preparation should not be described as the same medicine as an approved branded tablet merely because both mention semaglutide.
Start with the full name
Record the branded or compounded name, formulation, route, and pharmacy. A product used inside the cheek is not automatically an ordinary swallowed tablet, and a sublingual preparation is another route again. Those distinctions should be clear in the prescription and patient instructions rather than left to inference from a catalog heading.
Ask what the evidence actually studied
A provider may cite studies of an approved injectable or tablet. Ask whether that research concerns the exact finished product being proposed. Ingredient-level similarities do not by themselves establish the same clinical results for a different preparation, especially when route or additional ingredients differ.
Compare the complete arrangement
Price can include a different supply period, clinical service, or renewal commitment for each route. Ask what happens financially if the clinician changes the formulation. The Strut review and Rex MD review illustrate why a compounded lozenge and branded-tablet pathway require separate questions.
Leave treatment selection to the clinical discussion
Convenience and preferences matter, but they need to be considered with medical history, precautions, monitoring, and available treatments. Do not switch preparations or carry over instructions without the clinician and pharmacist’s guidance. Our approval-status guide explains why regulatory wording should stay product-specific.
Trace the information
Sources & research notes
Provider documents describe the provider’s own offer. Official medical references explain context; they do not endorse this publication or its featured partner.
- FDA: concerns with unapproved GLP-1 drugs Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs Regulatory / public agency · Checked September 22, 2026
- FDA: Wegovy semaglutide tablets, NDA 218316 approval letter Regulatory source · Checked September 22, 2026
- Strut Health: official program, pricing, and care details Provider-published information · Checked September 22, 2026
- Rex MD: official program, pricing, and care details Provider-published information · Checked September 22, 2026
Use this guide to prepare questions, not to choose or change a prescription without clinical advice. Research method · Commercial disclosure